The Beginning of Genomic Therapies for ALS

Affiliations

Editorial

Orla Hardiman et al. N Engl J Med. 2020.

. 2020 Jul 9;383(2):180-181.

doi: 10.1056/NEJMe2012930.

¹ From Trinity College and Beaumont Hospital, Dublin (O.H.); and University Medical Center, Utrecht, the Netherlands (L.H.B.).

No abstract available

Comment on

Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, Genge A, Glass J, Ladha S, Ludolph AL, Maragakis NJ, McDermott CJ, Pestronk A, Ravits J, Salachas F, Trudell R, Van Damme P, Zinman L, Bennett CF, Lane R, Sandrock A, Runz H, Graham D, Houshyar H, McCampbell A, Nestorov I, Chang I, McNeill M, Fanning L, Fradette S, Ferguson TA. Miller T, et al. N Engl J Med. 2020 Jul 9;383(2):109-119. doi: 10.1056/NEJMoa2003715. N Engl J Med. 2020. PMID: 32640130 Clinical Trial.